Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) shares hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as $98.82 and last traded at $99.69, with a volume of 1639059 shares trading hands. The stock had previously closed at $103.03.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently weighed in on SRPT shares. HC Wainwright reiterated a "sell" rating and set a $75.00 price objective on shares of Sarepta Therapeutics in a report on Thursday, February 27th. Scotiabank assumed coverage on Sarepta Therapeutics in a report on Friday, March 7th. They issued a "sector perform" rating and a $105.00 price target for the company. StockNews.com downgraded Sarepta Therapeutics from a "buy" rating to a "hold" rating in a report on Wednesday, November 20th. Piper Sandler cut their price target on Sarepta Therapeutics from $200.00 to $182.00 and set an "overweight" rating on the stock in a research note on Wednesday, November 27th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $202.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday, February 27th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $170.41.
Read Our Latest Stock Analysis on SRPT
Sarepta Therapeutics Stock Down 1.2 %
The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The stock has a market cap of $9.66 billion, a PE ratio of 79.60 and a beta of 0.79. The business has a 50 day moving average price of $113.27 and a 200 day moving average price of $120.70.
Insider Buying and Selling
In other Sarepta Therapeutics news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the completion of the transaction, the director now owns 22,840 shares of the company's stock, valued at $2,851,345.60. This represents a 31.49 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 7.70% of the stock is currently owned by insiders.
Hedge Funds Weigh In On Sarepta Therapeutics
A number of hedge funds have recently made changes to their positions in SRPT. Capital International Investors raised its holdings in shares of Sarepta Therapeutics by 38.9% during the fourth quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company's stock valued at $1,057,482,000 after acquiring an additional 2,437,855 shares during the last quarter. Norges Bank acquired a new position in shares of Sarepta Therapeutics during the fourth quarter valued at approximately $126,315,000. Wellington Management Group LLP raised its holdings in shares of Sarepta Therapeutics by 32.3% during the third quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company's stock valued at $340,527,000 after acquiring an additional 665,087 shares during the last quarter. Erste Asset Management GmbH acquired a new stake in shares of Sarepta Therapeutics in the third quarter valued at approximately $79,425,000. Finally, Janus Henderson Group PLC increased its holdings in shares of Sarepta Therapeutics by 14.2% in the third quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company's stock valued at $544,408,000 after purchasing an additional 543,143 shares during the last quarter. Institutional investors and hedge funds own 86.68% of the company's stock.
About Sarepta Therapeutics
(
Get Free Report)
Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.
Read More
Before you consider Sarepta Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sarepta Therapeutics wasn't on the list.
While Sarepta Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
